Jérôme Rapion

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

Emmanuelle Clappier, Auclerc Mf, Jérôme Rapion et al. · Leukemia · 2013 · 152 citations

Medicine, Genetics, Oncology +15

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève et al. · European Journal of Cancer · 2010 · 109 citations

Medicine, Oncology, Pharmacology +10

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

Emmanuelle Clappier, Nathalie Grardel, Marleen Bâkkus et al. · Leukemia · 2015 · 103 citations

Medicine, Hematology, Oncology +17

Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3‐98

Elżbieta Senkus, Henry Gómez, Luc Dirix et al. · Psycho-Oncology · 2013 · 78 citations

Medicine, Oncology, Chemotherapy +14

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

Roel Willemze, Stefan Suciu, Petra Muus et al. · Annals of Hematology · 2014 · 12 citations

Medicine, Oncology, Pharmacotherapy +14